Últimas noticias sobre Cumberland (NASDAQ:CPIX) Bolsa

Cumberland

Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.

Cumberland Pharmaceuticals Inc. - Common Stock

Cumberland Pharmaceuticals Inc

WIIM

CPIX

Cumberland Pharmaceuticals shares are trading higher after the company announced it published a study investigating Caldolor in older patients.

Biotech

News

General

Cumberland Pharmaceuticals Publishes Study Investigating Caldolor In Older Patients

Cumberland leveraging Qureight's deep-learning AI platform&nbsp; for its Phase II FIGHTING FIBROSIS&#x2122; clinical trial

Cumberland Pharmaceuticals And Qureight Partner To Advance Idiopathic Pulmonary Fibrosis Treatment Research

<h3>Gainers</h3>
<ul>
<li>Lipocine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>) shares rose 15.1% to $3.66 during Tuesday's after-market session. The company's market cap stands at $19.5 million. </li>
<li>Cumberland (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) shares increased by 11.11% to $4.9. The market value of their outstanding shares is at $68.4 million. As per the news, the Q1 earnings report came out today. </li>
<li>Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) shares moved upwards by 10.89% to $20.25. The market value of their outstanding shares is at $356.7 million. The company's, Q1 earnings came out today. </li>
<li>Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) stock moved upwards by 10.0% to $0.33. The company's market cap stands at $14.5 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares moved upwards by 9.84% to $0.42. The company's market cap stands at $11.8 million. </li>
<li>Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) shares rose 9.35% to $0.49. The market value of their outstanding shares is at $71.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) stock fell 20.7% to $37.0 during Tuesday's after-market session. The company's market cap stands at $3.6 billion. The company's, Q1 earnings came out today. </li>
<li>Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) stock decreased by 18.44% to $5.93. The company's market cap stands at $546.5 million. As per the news, the Q1 earnings report came out today. </li>
<li>AquaBounty Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQB#NASDAQ">AQB</a>) shares decreased by 16.87% to $0.78. The market value of their outstanding shares is at $3.0 million. </li>
<li>Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) stock fell 8.82% to $3.0. The company's market cap stands at $4.4 million. </li>
<li>Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) stock fell 8.49% to $1.51. The market value of their outstanding shares is at $2.9 million. </li>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) shares fell 8.48% to $1.08. The company's market cap stands at $4.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ATNF

BDSX

EVOK

HBIO

LPCN

MYGN

ONMD

RIGL

SRPT

THAR

12 Health Care Stocks Moving In Tuesday's After-Market Session

Cumberland Pharmaceuticals shares are trading higher after the company reported a year-over-year increase in Q1 financial results.

Cumberland (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) reported quarterly earnings of $0.16 per share. This is a 420 percent increase over losses of $(0.05) per share from the same period last year. The company reported $11.71 million in sales this quarter. This is a 37.83 percent increase over sales of $8.50 million the same period last year.

Earnings

Cumberland Q1 Adj. EPS $0.16 Up From $(0.05) YoY, Sales $11.71M Up From $8.50M YoY

ACLS

AHCO

ALAB

ALGS

ALGT

AMTM

ANDE

ANET

ANGI

ARDT

ARIS

ARMK

ARQT

ARRY

ATKR

ATOM

ATRO

AUDC

AVNS

AVNT

AVNW

AZEK

BALL

BBNX

BCAB

BLDP

BRLT

BWIN

BWMN

CCCS

CCLD

CDRE

CELH

CGAU

CGBD

CHMI

CHRD

CIFR

CIGI

CLDT

CLOV

COTY

CPAY

CPNG

CRCT

CRIS

CRMD

CRSR

CRUS

CURI

CVGI

CXDO

CYTK

DASH

DAWN

DDOG

DOCN

DRCT

DRVN

DVAX

ENLT

EOSE

Embraer-Empresa Brasileira De Aeronautica

ESPR

EVGO

Earnings Scheduled For May 6, 2025

<h3>Gainers</h3>
<ul>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) shares rose 39.9% to $0.7 during Friday's after-market session. The company's market cap stands at $7.1 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) shares rose 14.86% to $1.7. The company's market cap stands at $1.2 million. </li>
<li>Aspira Womens Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) stock increased by 13.76% to $0.1. The market value of their outstanding shares is at $1.7 million. </li>
<li>Jin Medical International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJYL#NASDAQ">ZJYL</a>) shares moved upwards by 9.42% to $0.72. The market value of their outstanding shares is at $112.7 million. </li>
<li>Know Labs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KNW#AMEX">KNW</a>) shares increased by 8.26% to $1.31. The market value of their outstanding shares is at $3.6 million. </li>
<li>Cumberland (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) shares moved upwards by 6.98% to $4.91. The market value of their outstanding shares is at $68.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares declined by 17.1% to $4.11 during Friday's after-market session. The market value of their outstanding shares is at $47.2 million. </li>
<li>HeartSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSCS#NASDAQ">HSCS</a>) stock fell 10.66% to $2.6. The market value of their outstanding shares is at $2.8 million. </li>
<li>TriSalus Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSI#NASDAQ">TLSI</a>) stock fell 9.58% to $5.1. The market value of their outstanding shares is at $155.5 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) stock decreased by 9.34% to $1.07. The market value of their outstanding shares is at $6.3 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) stock fell 8.04% to $1.03. </li>
<li>Wellgistics Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGRX#NASDAQ">WGRX</a>) shares fell 7.87% to $4.57. The company's market cap stands at $237.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HSCS

PSTV

RNAZ

TCBP

TLSI

WGRX

WINT

ZJYL

12 Health Care Stocks Moving In Friday's After-Market Session

Ifetroban demonstrated significant 5.4% improvement in cardiac function

Events

Cumberland Pharmaceuticals Announced Results From Its Phase 2 FIGHT DMD Clinical Trial Were Selected For Late-breaking Presentation At The Muscular Dystrophy Association Clinical & Scientific Conference In Dallas

Cumberland (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) reported quarterly losses of $(0.02) per share. This is a 81.82 percent increase over losses of $(0.11) per share from the same period last year. The company reported $10.44 million in sales this quarter. This is a 11.58 percent increase over sales of $9.35 million the same period last year.

Cumberland Q4 Adj EPS $(0.02) Up From $(0.11) YoY, Sales $10.44M Up From $9.35M YoY

<h3>Companies Reporting Before The Bell</h3>
• 908 Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASS#NASDAQ">MASS</a>) is likely to report quarterly loss at $0.37 per share on revenue of $16.18 million. 
• Plug Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) is projected to report quarterly loss at $0.23 per share on revenue of $262.65 million. 
• NexGen Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NXE#NYSE">NXE</a>) is projected to report earnings for its fourth quarter. 
• EVgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGO#NASDAQ">EVGO</a>) is estimated to report quarterly loss at $0.09 per share on revenue of $69.00 million. 
• L.B. Foster (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSTR#NASDAQ">FSTR</a>) is estimated to report quarterly earnings at $0.22 per share on revenue of $131.48 million. 
• WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) is estimated to report quarterly loss at $0.24 per share on revenue of $25.59 million. 
• InfuSystems Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INFU#AMEX">INFU</a>) is projected to report quarterly earnings at $0.08 per share on revenue of $34.40 million. 
• Amylyx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLX#NASDAQ">AMLX</a>) is expected to report earnings for its fourth quarter. 
• Neuronetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STIM#NASDAQ">STIM</a>) is projected to report quarterly loss at $0.24 per share on revenue of $18.98 million. 
• Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) is estimated to report quarterly loss at $0.12 per share on revenue of $26.94 million. 
• Olaplex Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLPX#NASDAQ">OLPX</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $87.51 million. 
• Hagerty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HGTY#NYSE">HGTY</a>) is expected to report quarterly earnings at $0.01 per share on revenue of $279.58 million. 
• Angel Oak Mortgage REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOMR#NYSE">AOMR</a>) is expected to report quarterly earnings at $0.27 per share on revenue of $9.99 million. 
• Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) is estimated to report quarterly loss at $0.13 per share on revenue of $63.06 million. 
• Sophia Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPH#NASDAQ">SOPH</a>) is expected to report quarterly loss at $0.15 per share on revenue of $17.71 million. 
• Paysafe (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSFE#NYSE">PSFE</a>) is projected to report quarterly earnings at $0.72 per share on revenue of $437.22 million. 
• Compugen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEN#NASDAQ">CGEN</a>) is likely to report quarterly loss at $0.07 per share on revenue of $24.96 million. 
• Sea (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) is expected to report quarterly earnings at $0.70 per share on revenue of $4.60 billion. 
• Genius Sports (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GENI#NYSE">GENI</a>) is estimated to report quarterly earnings at $0.07 per share on revenue of $175.71 million. 
• On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) is expected to report quarterly earnings at $0.18 per share on revenue of $593.34 million. 
• Nayax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYAX#NASDAQ">NYAX</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $91.89 million. 
• Best Buy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) is likely to report quarterly earnings at $2.42 per share on revenue of $13.69 billion. 
• Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) is likely to report quarterly earnings at $2.65 per share on revenue of $30.28 billion. 
• CPI Card (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMTS#NASDAQ">PMTS</a>) is estimated to report quarterly earnings at $0.57 per share on revenue of $118.97 million. 
• Wag Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) is likely to report quarterly earnings at $0.40 per share on revenue of $290.88 million. 
• Modiv Industrial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDV#NYSE">MDV</a>) is expected to report quarterly earnings at $0.27 per share on revenue of $11.86 million. 
• AutoZone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) is estimated to report quarterly earnings at $29.90 per share on revenue of $4.00 billion. 
<h3>Companies Reporting After The Bell</h3>
• Medallion Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFIN#NASDAQ">MFIN</a>) is expected to report quarterly earnings at $0.33 per share on revenue of $53.66 million. 
• Southland Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SLND#AMEX">SLND</a>) is projected to report quarterly loss at $0.49 per share on revenue of $230.13 million. 
• Gulf Island Fabrication (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIFI#NASDAQ">GIFI</a>) is expected to report quarterly earnings at $0.12 per share on revenue of $41.00 million. 
• Cumberland (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) is projected to report earnings for its fourth quarter. 
• Baytex Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTE#NYSE">BTE</a>) is estimated to report quarterly earnings at $0.16 per share on revenue of $980.40 million. 
• Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) is estimated to report quarterly earnings at $0.39 per share on revenue of $26.54 million. 
• ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) is estimated to report quarterly earnings at $0.02 per share on revenue of $26.52 million. 
• Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) is expected to report quarterly earnings at $0.33 per share on revenue of $57.60 million. 
• Astronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRO#NASDAQ">ATRO</a>) is likely to report quarterly earnings at $0.28 per share on revenue of $194.91 million. 
• Fuel Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEK#NASDAQ">FTEK</a>) is expected to report quarterly loss at $0.03 per share on revenue of $5.63 million. 
• comScore (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCOR#NASDAQ">SCOR</a>) is likely to report quarterly earnings at $0.36 per share on revenue of $91.66 million. 
• Alpha Teknova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKNO#NASDAQ">TKNO</a>) is estimated to report quarterly loss at $0.12 per share on revenue of $8.78 million. 
• Mayville Engineering (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEC#NYSE">MEC</a>) is projected to report quarterly loss at $0.08 per share on revenue of $124.13 million. 
• NeuroPace (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPCE#NASDAQ">NPCE</a>) is estimated to report quarterly loss at $0.24 per share on revenue of $21.11 million. 
• ATN International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNI#NASDAQ">ATNI</a>) is projected to report quarterly loss at $0.19 per share on revenue of $179.11 million. 
• Stem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) is projected to report quarterly loss at $0.16 per share on revenue of $49.37 million. 
• OrthoPediatrics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>) is projected to report quarterly loss at $0.26 per share on revenue of $52.70 million. 
• Ascent Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACNT#NASDAQ">ACNT</a>) is expected to report earnings for its fourth quarter. 
• Ecopetrol (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EC#NYSE">EC</a>) is estimated to report quarterly earnings at $0.41 per share on revenue of $7.68 billion. 
• Horizon Tech Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRZN#NASDAQ">HRZN</a>) is projected to report quarterly earnings at $0.32 per share on revenue of $25.68 million. 
• Owlet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWLT#NYSE">OWLT</a>) is expected to report quarterly loss at $0.48 per share on revenue of $16.92 million. 
• AeroVironment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>) is expected to report quarterly earnings at $0.86 per share on revenue of $214.00 million. 
• Ross Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) is estimated to report quarterly earnings at $1.67 per share on revenue of $5.95 billion. 
• Evolus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOLS#NASDAQ">EOLS</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $77.23 million. 
• Eos Energy Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) is expected to report quarterly loss at $0.20 per share on revenue of $6.23 million. 
• CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) is expected to report quarterly loss at $0.31 per share on revenue of $58.79 million. 
• Ingram Micro Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INGM#NYSE">INGM</a>) is likely to report quarterly earnings at $0.90 per share on revenue of $13.22 billion. 
• ChargePoint Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHPT#NYSE">CHPT</a>) is likely to report quarterly loss at $0.07 per share on revenue of $100.97 million. 
• Credo Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) is estimated to report quarterly earnings at $0.18 per share on revenue of $120.31 million. 
• Crexendo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CXDO#NASDAQ">CXDO</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $15.64 million. 
• CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) is estimated to report quarterly earnings at $0.86 per share on revenue of $1.03 billion. 
• Ooma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OOMA#NYSE">OOMA</a>) is likely to report quarterly earnings at $0.16 per share on revenue of $64.70 million. 
• Custom Truck One Source (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTOS#NYSE">CTOS</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $539.81 million. 
• Cricut (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRCT#NASDAQ">CRCT</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $214.41 million. 
• Orion Gr Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORN#NYSE">ORN</a>) is estimated to report quarterly earnings at $0.19 per share on revenue of $272.70 million. 
• Latham Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIM#NASDAQ">SWIM</a>) is likely to report quarterly loss at $0.01 per share on revenue of $84.95 million. 
• Box (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOX#NYSE">BOX</a>) is estimated to report quarterly earnings at $0.41 per share on revenue of $278.60 million. 
• Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) is projected to report quarterly earnings at $0.91 per share on revenue of $223.23 million. 
• Weyco Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEYS#NASDAQ">WEYS</a>) is projected to report earnings for its fourth quarter. 
• Sociedad Quimica Y Minera (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQM#NYSE">SQM</a>) is likely to report quarterly earnings at $0.84 per share on revenue of $1.13 billion. 
• Nordstrom (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>) is likely to report quarterly earnings at $0.90 per share on revenue of $4.33 billion. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACNT

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

AOMR

ATNI

AVAV

CDXC

CGEN

CHPT

CRDO

CRWD

CTOS

CYRX

EOLS

FSTR

FTEK

GENI

GIFI

HGTY

HRZN

INFU

INGM

KIDS

MASS

MFIN

NPCE

Nuveen Arizona Dividend Advantage Municipal Funds 3

NYAX

OLPX

ONON

OOMA

OWLT

PLUG

PMTS

PSFE

ROST

SCOR

SLND

SOPH

STEM

STIM

SWIM

TKNO

WEYS

YMAB

Earnings Scheduled For March 4, 2025

Cumberland Pharmaceuticals shares are trading higher on possible continued strength after the company announced yesterday that the National Medical Products Administration approved its Vibativ injection in China.

Vibativ is an antibiotic for pneumonia and serious skin infections
Approval in China paves the way for launch in world's second-largest market

Health Care

Cumberland Pharmaceuticals And SciClone Pharmaceuticals Announced The National Medical Products Administration Approval Of Cumberland's Vibativ (Telavancin) Injection In China

Trading Ideas

Cumberland Pharmaceuticals Shares Resumed Trade

Cumberland Pharmaceuticals Shares Halted On Circuit Breaker To The Downside, Stock Now Up 38.3%

On Tuesday, Cumberland Pharmaceuticals Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) released topline results from its <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43459112/cumberland-pharmaceuticals-announces-breakthrough-results-from-the-phase-2-fight-dmd-trial-in-duch" rel="noreferrer noopener">Phase 2 FIGHT DMD trial</a>.
The study evaluated ifetroban, a novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease – the leading cause of <a target="_blank" href="https://www.benzinga.com/quote/CPIX" rel="noreferrer noopener">death in DMD patients</a>.
DMD is a rare and incurable pediatric disease caused by mutations in the gene encoding dystrophin, a protein critical for muscle function, including the heart.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42419338/why-is-cumberland-pharmaceuticals-stock-trading-over-100-on-tuesday" rel="noreferrer noopener">Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on Tuesday?</a>
Patients with DMD slowly lose muscle function, resulting in the inability to walk, difficulty breathing, and heart failure.
The trial enrolled 41 patients who received either low-dose ifetroban (150 mg per day), high-dose ifetroban (300 mg per day), or placebo.
The study&#8217;s primary endpoint was an improvement in the heart&#8217;s left ventricular ejection fractions (LVEF), a key indicator of how well the heart is pumping blood.&nbsp;
Key findings include:
<ul>
<li>High-dose ifetroban treatment resulted in an overall 3.3% improvement in LVEF.</li>
<li>The high-dose ifetroban group showed an increase in 1.8% in LVEF, while the study placebo group showed an expected decline in LVEF of 1.5%</li>
<li>The difference was even more pronounced when compared with propensity-matched natural history controls, with the high-dose treatment providing a significant 5.4% overall improvement in LVEF, while the control patients experienced a 3.6% decline.</li>
<li>Both doses of ifetroban were well-tolerated, with no serious drug-related events.</li>
</ul>
Ifetroban has received both&nbsp;Orphan Drug Designation&nbsp;and&nbsp;Rare Pediatric Disease Designation&nbsp;from the FDA. If approved, ifetroban would be the first therapy specifically indicated for DMD-related heart disease.
Price Action: CPIX stock is up 23.01% at $2.62 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43459558/novo-nordisk-faces-investor-concerns-over-hybrid-cagrisema-trial-results-for-weight-loss" target="_blank" rel="noreferrer noopener">Novo Nordisk Faces Investor Concerns Over Hybrid CagriSema Trial Results For Weight Loss</a></li>
</ul>

Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease

Cumberland Pharmaceuticals shares are trading higher after the company announced advance results from the Phase 2 Fight DMD trial in Duchenne muscular dystrophy heart disease.

Cumberland Pharmaceuticals Announces Advance Results From The Phase 2 FIGHT DMD Trial In Duchenne Muscular Dystrophy Heart Disease

<h3>Gainers</h3>
<ul>
<li>Chimerix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMRX#NASDAQ">CMRX</a>) shares moved upwards by 150.9% to $2.17 during Tuesday's pre-market session. The market value of their outstanding shares is at $195.1 million. </li>
<li>Cumberland (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) shares rose 136.29% to $2.93. The company's market cap stands at $41.1 million. </li>
<li>Cardiff Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDF#NASDAQ">CRDF</a>) shares rose 47.54% to $3.6. The market value of their outstanding shares is at $184.0 million. </li>
<li>NewAmsterdam Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAMS#NASDAQ">NAMS</a>) stock rose 35.74% to $25.14. The market value of their outstanding shares is at $2.3 billion. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock moved upwards by 31.88% to $2.73. The market value of their outstanding shares is at $2.3 million. </li>
<li>Gelteq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GELS#NASDAQ">GELS</a>) stock increased by 23.87% to $4.41. The company's market cap stands at $41.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) stock decreased by 73.8% to $2.69 during Tuesday's pre-market session. The company's market cap stands at $22.2 million. </li>
<li>Biora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOR#NASDAQ">BIOR</a>) stock fell 47.78% to $0.7. The company's market cap stands at $3.1 million. </li>
<li>Radiopharm Theranostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RADX#NASDAQ">RADX</a>) stock decreased by 23.75% to $7.0. The market value of their outstanding shares is at $15.2 billion. </li>
<li>Iterum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRM#NASDAQ">ITRM</a>) shares declined by 16.87% to $2.42. The market value of their outstanding shares is at $66.5 million. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) shares declined by 15.07% to $0.41. The market value of their outstanding shares is at $1.6 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) shares decreased by 13.64% to $0.95. The company's market cap stands at $16.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BIOR

BSGM

CMRX

CRDF

CRVO

GELS

ITRM

NAMS

RADX

SXTC

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

U.S. stocks traded mixed toward the end of trading, with the S&amp;P 500 falling by around 0.1% on Tuesday.
The Dow traded down 0.02% to 44,393.25 while the NASDAQ rose 0.03% to 19,743.54. The S&amp;P 500 also fell, dropping, 0.06% to 6,049.44.
Check This Out: <a href="https://www.benzinga.com/24/12/42413544/how-to-earn-500-a-month-from-macys-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Macy&#8217;s Stock Ahead Of Q3 Earnings</a>
Leading and Lagging Sectors Communication services shares jumped by 2.3% on Tuesday.
In trading on Tuesday, real estate shares fell by 1%.
Top Headline
On Tuesday, AutoZone, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) reported weaker-than-expected earnings and sales results for its fiscal first quarter.
The company posted earnings per share of $32.52, missing the Street view of $33.76. Quarterly revenues of $4.28 billion (+2.1% year over year) missed the analyst consensus of $4.30 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Chimerix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMRX#NASDAQ">CMRX</a>) shares shot up 213% to $2.71 after the company announced it will submit dordaviprone for accelerated approval to the FDA for patients with recurrent H3 K27M-mutant diffuse glioma.</li>
<li>Shares of Cumberland Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) got a boost, surging 94% to $2.4001 after the company announced the FDA has approved its supplemental new drug application for acetadote.</li>
<li>uniQure N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QURE#NASDAQ">QURE</a>) shares were also up, gaining 129% to $16.71 after the company announced an agreement with the FDA on key elements of an accelerated pathway for AMT-130.</li>
</ul>
Equities Trading DOWN
<ul>
<li>CervoMed Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) shares dropped 77% to $2.34 after the company announced its Phase 2b trial of Neflamapimod failed to meet its key endpoints for the treatment of dementia.</li>
<li>Shares of Yext, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YEXT#NYSE">YEXT</a>) were down 17% to $7.07 following third-quarter results.</li>
<li>MEDIROM Healthcare Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRM#NASDAQ">MRM</a>) was down, falling 46% to $1.52. MEDIROM Healthcare priced its $5 million public offering of 2.86 million American Depositary Shares at $1.75 per ADS.</li>
</ul>
Commodities In commodity news, oil traded up 0.7% to $68.84 while gold traded up 1.2% at $2,718.80.
Silver traded up 0.4% to $32.73 on Tuesday, while copper fell 0.1% to $4.2730.
Euro zone
European shares closed lower today. The eurozone's STOXX 600 fell 0.52%, Germany's DAX fell 0.08% and France's CAC 40 fell 1.14%. Spain's IBEX 35 Index fell 0.38%, while London's FTSE 100 fell 0.86%.
Asia Pacific Markets
Asian markets closed mixed on Monday, with Japan's Nikkei 225 gaining 0.18%, Hong Kong's Hang Seng Index gaining 2.76%, China's Shanghai Composite Index falling 0.05% and India's BSE Sensex falling 0.25%.
Economics
U.S. nonfarm business sector labor productivity increased by 2.2% in the third quarter, in-line with the preliminary reading.&nbsp;&nbsp;&nbsp;&nbsp;
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42412458/amazon-to-rally-around-15-here-are-10-top-analyst-forecasts-for-tuesday">Amazon To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Eurozone

Intraday Update

Markets

QURE

YEXT

S&P 500 Edges Lower; AutoZone Posts Downbeat Earnings

Press Releases

Stocks to Watch in December 2025: LDTC, CPIX, PNPN.V, ZEO, and More Inside

Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease

VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS

Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth

FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2025 FINANCIAL RESULTS & COMPANY UPDATE

Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025

Comments

Cumberland

Noticias

Últimas noticias sobre Cumberland (NASDAQ:CPIX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL